Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SARS-COV-2 Screening in Dialysis Facilities: Building an Optimal Strategy to Protect High Risk Populations

NCT05225298 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05225298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05225298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SARS-COV-2 Screening in Dialysis Facilities: Building an Optimal Strategy to Protect High Risk Populations
Lead sponsor
Stanford University
Phase
Not applicable
Overall status
Completed
Start date
February 6, 2023
Completion date
October 1, 2023
Enrollment
2,389 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dialysis; complications, end-stage renal disease, sars-cov-2 acute respiratory disease